Prospective Single-arm, Single-center Clinical Study of Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Regimen in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma
This is a prospective, single-arm, single-center clinical study. This clinical study aims to explore the efficacy and safety of the ZPR（Zanubrutinib, Polatuzumab vedotin and Rituximab）regimen in elderly patients with treatment-naive diffuse large B-cell lymphoma.
⁃ Patients must meet all of the following inclusion criteria to be enrolled in this study:
• Patients with histopathologically confirmed DLBCL;
• Patients haven't received any anti-DLBCL therapy. Corticosteroids alone is not considered as a line of treatment;
• The age of patients ≥ 70 years old, or between 60 and 69 but with an ECOG score between 2-4;
• Patients intolerant to standard front-line therapy, i.e. R-CHOP, or R-miniCHOP etc.
• Good organ function;
• Measurable lesions detected by radiological imaging were defined as the longest diameter of at least 1 lymph node lesion \> 1.5 cm, or the longest diameter of at least 1 extranodal lesion \> 1.0 cm, and at least 2 vertical diameters that could be accurately measured;
• Life expectancy ≥ 6 months;
• Sign written informed consent.